Doig Craig L, Zielinska Agnieszka E, Fletcher Rachel S, Oakey Lucy A, Elhassan Yasir S, Garten Antje, Cartwright David, Heising Silke, Alsheri Ahmed, Watson David G, Prehn Cornelia, Adamski Jerzy, Tennant Daniel A, Lavery Gareth G
Institute of Metabolism and Systems Research, University of Birmingham, 2nd Floor IBR Tower, Edgbaston, Birmingham, B15 2TT, UK.
Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK.
Skelet Muscle. 2020 Feb 19;10(1):5. doi: 10.1186/s13395-019-0216-z.
Hexose-6-Phosphate Dehydrogenase (H6PD) is a generator of NADPH in the Endoplasmic/Sarcoplasmic Reticulum (ER/SR). Interaction of H6PD with 11β-hydroxysteroid dehydrogenase type 1 provides NADPH to support oxo-reduction of inactive to active glucocorticoids, but the wider understanding of H6PD in ER/SR NAD(P)(H) homeostasis is incomplete. Lack of H6PD results in a deteriorating skeletal myopathy, altered glucose homeostasis, ER stress and activation of the unfolded protein response. Here we further assess muscle responses to H6PD deficiency to delineate pathways that may underpin myopathy and link SR redox status to muscle wide metabolic adaptation.
We analysed skeletal muscle from H6PD knockout (H6PDKO), H6PD and NRK2 double knockout (DKO) and wild-type (WT) mice. H6PDKO mice were supplemented with the NAD precursor nicotinamide riboside. Skeletal muscle samples were subjected to biochemical analysis including NAD(H) measurement, LC-MS based metabolomics, Western blotting, and high resolution mitochondrial respirometry. Genetic and supplement models were assessed for degree of myopathy compared to H6PDKO.
H6PDKO skeletal muscle showed adaptations in the routes regulating nicotinamide and NAD biosynthesis, with significant activation of the Nicotinamide Riboside Kinase 2 (NRK2) pathway. Associated with changes in NAD biosynthesis, H6PDKO muscle had impaired mitochondrial respiratory capacity with altered mitochondrial acylcarnitine and acetyl-CoA metabolism. Boosting NAD levels through the NRK2 pathway using the precursor nicotinamide riboside elevated NAD/NADH but had no effect to mitigate ER stress and dysfunctional mitochondrial respiratory capacity or acetyl-CoA metabolism. Similarly, H6PDKO/NRK2 double KO mice did not display an exaggerated timing or severity of myopathy or overt change in mitochondrial metabolism despite depression of NAD availability.
These findings suggest a complex metabolic response to changes in muscle SR NADP(H) redox status that result in impaired mitochondrial energy metabolism and activation of cellular NAD salvage pathways. It is possible that SR can sense and signal perturbation in NAD(P)(H) that cannot be rectified in the absence of H6PD. Whether NRK2 pathway activation is a direct response to changes in SR NAD(P)(H) availability or adaptation to deficits in metabolic energy availability remains to be resolved.
己糖-6-磷酸脱氢酶(H6PD)是内质网/肌浆网(ER/SR)中烟酰胺腺嘌呤二核苷酸磷酸(NADPH)的生成酶。H6PD与1型11β-羟基类固醇脱氢酶相互作用,提供NADPH以支持无活性糖皮质激素向活性糖皮质激素的氧化还原反应,但对于H6PD在ER/SR中烟酰胺腺嘌呤二核苷酸(NAD)/烟酰胺腺嘌呤二核苷酸磷酸(NADP)(H)稳态中的更广泛理解尚不完整。缺乏H6PD会导致骨骼肌病恶化、葡萄糖稳态改变、内质网应激和未折叠蛋白反应激活。在此,我们进一步评估肌肉对H6PD缺乏的反应,以描绘可能导致肌病的途径,并将肌浆网氧化还原状态与肌肉整体代谢适应联系起来。
我们分析了H6PD基因敲除(H6PDKO)、H6PD和NRK2双基因敲除(DKO)以及野生型(WT)小鼠的骨骼肌。给H6PDKO小鼠补充NAD前体烟酰胺核糖。对骨骼肌样本进行生化分析,包括NAD(H)测量、基于液相色谱-质谱联用的代谢组学、蛋白质免疫印迹和高分辨率线粒体呼吸测定。与H6PDKO相比,评估基因和补充模型的肌病程度。
H6PDKO骨骼肌在调节烟酰胺和NAD生物合成的途径中表现出适应性变化,烟酰胺核糖激酶2(NRK2)途径显著激活。与NAD生物合成的变化相关,H6PDKO肌肉的线粒体呼吸能力受损,线粒体酰基肉碱和乙酰辅酶A代谢改变。使用前体烟酰胺核糖通过NRK2途径提高NAD水平可升高NAD/NADH,但对减轻内质网应激、线粒体呼吸功能障碍或乙酰辅酶A代谢没有作用。同样,尽管NAD可用性降低,但H6PDKO/NRK2双基因敲除小鼠并未表现出肌病时间或严重程度的加剧,或线粒体代谢的明显变化。
这些发现表明,肌肉肌浆网NADP(H)氧化还原状态变化会引发复杂的代谢反应,导致线粒体能量代谢受损和细胞NAD补救途径激活。在缺乏H6PD的情况下,肌浆网有可能感知并发出NAD(P)(H)扰动信号,而这种扰动无法得到纠正。NRK2途径的激活是对肌浆网NAD(P)(H)可用性变化的直接反应,还是对代谢能量可用性不足的适应,仍有待解决。